Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of subcutaneous amlitelimab in adults with moderate-to-severe asthma (Japan)
jRCT2031240069Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised trial in asthma comparing Treatment group 1: SC amlitelimab with Treatment group 2: SC placebo (2 arms). Primary endpoint: Percentage of participants with treatment-emergent adverse events. Started May 2024; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031240069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240069.